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Abstract
Sustaining the impact of hepatitis B virus (HBV) vaccination on incidence and prevalence of
HBV infection requires increasing and maintaining the uptake of vaccine among those at risk.
In recent years, the level of vaccine uptake among people who inject drugs (PWID) in the UK
has levelled-off. Data (2015–2016) from the national unlinked-anonymous monitoring survey
of PWID, an annual survey that collects data from PWID across England, Wales and
Northern Ireland, were used to examine HBV vaccine uptake. Data from participants who
had injected drugs during the previous year were used to investigate sources of hepatitis B vac-
cine doses as well as factors associated with vaccine uptake. Among the 3175 anti-HBc-nega-
tive participants, 3138 (99%) reported their vaccination status; 23% (714) reported no vaccine
uptake. Among those not vaccinated, 447 (63%) reported being sexually active and 116 (16%)
reported sharing needles and syringes. Majority of those not vaccinated reported accessing
services in the previous year that could have provided hepatitis B vaccine doses. These missed
opportunities for vaccinating of PWID indicate a need for additional targeted interventions.
Introduction
It is estimated that over 2 billion people worldwide have been infected with HBV, and that of
these, 257 million have chronic infection [1, 2]. About 780 000 people die each year due to the
consequences of hepatitis B such as cirrhosis and liver cancer [3–5]. The risk of developing
chronic hepatitis B infection depends on the age at which infection is acquired. Chronic infec-
tion will develop in up to 90% of children who acquire infection before the first year of life [3].
Among adults, approximately 5–10% of those infected with HBV will develop chronic infec-
tion and 15% of those adults will develop chronic liver disease, including cirrhosis, liver failure
and liver cancer [6]. Around a quarter of all liver disease cases in the UK are due to hepatitis
infections [7].
When not treated, HBV is highly contagious and is transmitted through contact with infec-
tious blood, semen or other bodily fluids through sexual contact with an infected person or
through other percutaneous or permucosal exposures. People who inject drugs (PWID) can
therefore be at high risk through unsafe injecting practice and often have a high prevalence
of viral hepatitis. Prioritisation of PWID and also the prison population as the key groups
for screening and treatment of viral hepatitis has therefore been advocated [8].
Hepatitis B is preventable with safe, effective and relatively inexpensive vaccines. A vaccine
against hepatitis B virus (HBV) has been available since 1982 [4, 8, 9]. Despite this, HBV
remains a major global health problem [3, 5, 10]. Although public health activities to control
viral hepatitis have increased in the last three decades, interventions for prevention have not
always been implemented sufficiently [2]. Since 1991, the World Health Organisation
(WHO) has recommended the addition of HBV immunisation to all national immunisation
programmes, but by 2004, many countries had still not implemented universal childhood
immunisation [4]. Childhood HBV immunisation has since been scaled up globally and global
coverage with the three doses of hepatitis B vaccine in infancy had reached 84% by 2015 [1].
Viral hepatitis continues to be a major public health threat even though new and effective
treatments have been developed. Public health responses have differed between countries, and
opportunities for action have not always been fully and effectively utilised. The WHO pub-
lished the first global health sector strategy on viral hepatitis in 2016 which has the goal of
eliminating viral hepatitis by 2030 [1]. The strategy contributes to the 2030 agenda for sustain-
able development [2] and covers all types of viral hepatitis but focuses on hepatitis B and hepa-
titis C because together these represent 95% of the viral hepatitis burden [1].
The strategy emphasises that vaccination is the key intervention for achieving the hepatitis B
targets. In addition to efforts at strengthening childhood immunisation programmes, vaccine
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must be made available to all and uptake monitored across all popu-
lation groups in all countries [1]. The UK signed up to this strategy
in May 2016.
Like many other western European countries, the prevalence of
HBV infection in the general population of the UK is low (<1%).
Based on the overall low incidence of HBV, and with the risk of
infection determined mainly by country of birth, ethnicity and
adult risk behaviours such as injecting drug use, the UK has
from 1988 until recently had a targeted hepatitis B vaccination
programme focused on higher risk groups [7, 11, 12]. These
groups include PWID and those at sexual risk (men who have
sex with men and sex workers). As childhood infection accounted
for an estimated 21% of all new chronic infections acquired in the
UK [12], universal screening of pregnant women for hepatitis B
and immunisation of babies at risk has been in place since
2000. The UK introduced a universal infant hepatitis B vaccin-
ation programme in August 2017 [13].
The UK has a well-established and extensive provision of ser-
vices for people who use drugs [14]. These drug services include
addiction services that offer interventions such as opiate substitu-
tion therapy (OST) and needle and syringe programmes (NSPs).
These services often provide hepatitis B vaccination and blood-
borne virus (BBV) testing [15]. The responsibility of commission-
ing of drug services has undergone changes over time notably so
in England, where they are now commissioned by the local gov-
ernment [16].
HBV vaccine uptake among PWID has increased from 56% [17,
18] in 2004 to 72% in 2016 [19]. There has been a decline in the
prevalence of anti-HBc, a marker of ever having been infected
with HBV, among PWID in the UK from 29% in 2004 [17, 18]
to 14% in 2016 [10]. This is probably related to the rise in vaccine
uptake. The prevalence of hepatitis B surface antigen (HBsAg), a
marker of current HBV infection, among anti-HBc-positive
PWID has declined from 4.8% in 2011 to 3.0% in 2016 [19].
Although the uptake of vaccination among PWID is high,
recent evidence suggests that this is no longer rising and may
have plateaued [19]. Transmission of hepatitis B is ongoing and
risky behaviours for BBV transmission, such as the sharing of
needles (17%), remain common among PWID in the UK [19].
Reaching and sustaining higher levels of HBV vaccination
among PWID is important in reducing transmission and
HBV-related morbidity and mortality. Despite frequent contact
with a range of health services that can provide hepatitis B vaccin-
ation in 2015 and 2016, a substantial proportion of PWID
remained unvaccinated.
Using data from a national bio-behavioural survey for 2015 and
2016, this paper aims to examine the sources of HBV vaccine for
those reporting to have ever received at least one dose of the vaccine.
The factors associated with HBV vaccine uptake were also examined
to explore how vaccine provision could be improved. Finally, contact
with health services by those not vaccinated is explored to assess the
potential missed opportunities for vaccination.
Methods
Sample frame, data collection and biological sample testing
PWID have been recruited into a voluntary unlinked-anonymous
monitoring (UAM) survey in the UK since 1990. Methodological
details of this series of annual cross-sectional surveys have been
published previously [20–22]. Briefly, agencies providing services
to PWID (e.g. NSPs and OST services) at sentinel locations
(N = 67) throughout the UK, except Scotland, invite clients who
have ever injected psychoactive drugs to participate in the survey.
Those who consent provide a biological sample, currently a dried
blood spot (DBS), and self-complete a questionnaire focused
on the injection of psychoactive drugs. The UAM survey has
multi-site ethics approval (NHS Health Research Authority
MREC/98/2/51). In 2013, questions on the use of health services
during the previous years were introduced into the survey ques-
tionnaire. Additionally, for the question asking about hepatitis
B vaccine uptake, those reporting vaccine uptake were asked to
indicate at which health services they received their doses of
HBV vaccine.
The DBS specimens collected by the survey were tested for
BBVs including the antibodies to hepatitis B core antigen
(anti-HBc). For anti-HBc, an-house IgG class-specific antibody
capture enzyme immunoassay (EIA) was used. Samples that
were anti-HBc-positive were then tested for HBsAg.
Data analysis
Data from 2015 and 2016 UAM survey waves were used.
Participants in 2016 who reported taking part in the survey in
2015 were excluded. Only anti-HBc-negative participants who
reported having injected drugs during the previous year were
included in the main analyses. Among those who reported having
received at least one dose of HBV vaccine, the number of doses
and source of vaccine were examined.
Bivariate analyses were undertaken to establish if there was an
association between the outcome variable (ever receiving a dose of
hepatitis B vaccine) and a number of key explanatory variables
including demographics, injecting practices and use of health ser-
vices. Where possible associations were found (P < 0.05); these
variables were further examined via multiple logistic regression
using forward stepwise procedure to select variables for inclusion
in the final model. All analyses were performed using SPSS 23.
For those not vaccinated, contact in the previous year with
health services offering vaccination was examined to determine
if there were any missed opportunities for vaccination.
Results
Sample characteristics
During 2015–2016, a total of 3652 participants reported injecting
drugs during the preceding year (26% female, mean age 38 years).
Of these, nine samples were insufficient for anti-HBc testing and
3643 samples were therefore tested, 468 (13%) of which were posi-
tive. Thus 3175 participants were anti-HBc-negative.
Of the 468 anti-HBc-positive samples, two samples were insuf-
ficient for anti-HBsAg testing, therefore 466 were tested, 14 (3%)
of which were positive. Overall 14/3641 (0.38%) of the total sam-
ples tested were currently infected with hepatitis B.
Among the 3175 anti-HBc-negative participants, 3138 (99%)
reported their vaccination status. In total, 2424 (76%) reported
receiving at least a single dose of HBV vaccine and 714 (23%)
reported that they had not been vaccinated for hepatitis B.
Sources of hepatitis B vaccine and number of hepatitis B
vaccine doses
Of the 2424 participants reporting hepatitis B vaccine uptake, 2239
(89%) reported the source of their vaccine doses. The main sources
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of vaccination were drug treatment services (49.9% (1117)) and
prisons (34.2% (766)). Fewer participants reported receiving vac-
cines from the other services such as NSP (16.4% (367)), general
practice (GP) or family doctor (11.3% (252)), sexually transmitted
infections/genitourinary medicine (STI/GUM) clinic (4.2% (94)),
emergency or casualty departments (A&E) (2.5% (57)) and hostel
or homeless services (1.9% (43)) (Fig. 1).
Of the 2239 reporting their vaccine sources, 2149 reported the
number of doses (‘jabs’). Though a single dose may offer some
protection, three doses are recommended to provide adequate
protection. The majority (59%) of those vaccinated reported
they had received three or more doses (Fig. 2).
Factors associated with uptake of hepatitis B vaccine
In the multivariable analysis, uptake of hepatitis B vaccine varied
with age with uptake being highest among those aged 40–49.
Vaccination was associated with ever being imprisoned, ever
been homeless, region of residence, engaging in transactional
sex and being sexually active the previous year (Table 1).
Regarding service usage, being vaccinated was associated with
having assessed an STI/GUM clinic, seeing a GP, being prescribed
treatment for drug use, with those currently prescribed treatment
more likely to be vaccinated than those prescribed treatment in
the past. Being vaccinated was also associated with the use of
an NSP with those who had used an NSP in the past more likely
to be vaccinated than those who had used the service in the pre-
vious year (Table 1).
Contact with health services during the previous year among
those not vaccinated
Among the 714 hepatitis B-negative participants reporting no vac-
cine uptake, the majority (87% (666)) had accessed at least one ser-
vice in the preceding year. Most (80% (569)) had used an NSP,
almost two-thirds (61% (437)) had been to a GP, over half (55%
(391)) were currently in addiction treatment, almost a third (29%
(205)) had attended A&E, 16% (115) had been to a walk-in clinic
and 7% (48) had been to an STI/GUM clinic. In addition, about a
half (49% (352)) had ever been to prison (Fig. 3).
Sexual and injecting risks among those not vaccinated for
hepatitis B
Among those unvaccinated for hepatitis B, 63% (447/714) reported
being sexually active in the previous year compared with 68% (1658/
2424) among those taking up the vaccine, whilst engaging in trans-
actional sex among those unvaccinated was reported by 5.3% (38)
vs. 7.1% (172) among those taking up the vaccine. Sharing needles
and syringes in the previous year was reported by 16% of both those
unvaccinated (116), and those taking up the vaccine (393). In the
previous year, 91% (651) among those unvaccinated reported inject-
ing heroin. However, injection of stimulant drugs was also common
with 35% (246) injecting crack. Less commonly injected drugs were




Hepatitis B vaccine uptake of 77% among PWIDs surveyed sug-
gests that the targeted HBV vaccine approach is reaching the
Fig. 1. Hepatitis B vaccine uptake and the sources of hepatitis B dose.
Fig. 2. Number of hepatitis B doses received.
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Table 1. Factors associated with hepatitis B vaccine uptake among PWID in the UK, 2015 and 2016
Characteristica Total Number vaccinated (%) P
Adjusted odds ratio, with 95%
confidence interval
All 3138 2424 77.2
Demographic
Age
<30 566 405 71.6 <0.001 1.00
30–39 665 499 75.0 1.034 0.785 1.361
40–50 734 599 81.6 1.446 1.088 1.921
>50 1173 921 78.5 1.215 0.938 1.574
Ever homeless
No 741 515 69.5 <0.001 1.00
Yes, not last year 1055 873 82.7 1.43 1.12 1.82
Yes, last year 1342 1036 77.2 1.12 0.90 1.40
Sex last year
No 1033 766 74.2 0.004 1.00
Yes 2105 1658 78.8 1.25 1.03 1.52
Ever been in prison
No 1061 699 65.9 <0.001 1.00
Yes 2077 1725 83.1 2.20 1.83 2.66
Engaged in transactional sex
Never 2719 2074 76.3 0.003 1.00
Yes but not in last year 209 178 85.2 1.51 1.00 2.28
Yes in last year 210 172 81.9 1.39 0.94 2.07
PHE region
North 1.00
Midlands and East of England 0.63 0.50 0.80
London 1.09 0.75 1.60
South 0.73 0.56 0.94
Wales and Northern Ireland 0.72 0.53 0.96
Injecting practise
Injected heroine in the last year
No 203 140 69.0 0.004 b
Yes 2935 2284 77.8
Health service usage last year
Used a sexual health, GUM/STI clinic
No 2790 2124 76.1 <0.001 1.00
Yes 348 300 86.2 2.33 1.64 3.29
Used a GP or family doctor
No 1007 730 72.5 <0.001 1.00
Yes 2131 1694 79.5 1.30 1.08 1.57
Used an NSP
No 187 102 54.5 <0.001 1.00
Yes, not last year 310 250 80.6 2.75 1.79 4.23
Yes, last year 2641 2072 78.5 2.40 1.73 3.33
(Continued )
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majority of PWID. However, in recent years, vaccination levels
have plateaued and HBV transmission among PWID continues,
indicating that vaccine uptake needs to increase further.
Data for 2015/16 from the National Drug Treatment
Monitoring Service (NDTMS) in England show a lower level of
vaccine uptake. Fifty per cent (8823/17756) among those who
have ever injected drugs and potentially at risk of hepatitis B
were vaccinated [19]. The difference in the reported uptake in
NDTMS and the UAM survey may reflect the UAM survey data
being self-reported and only for those who had injected drugs dur-
ing the previous year. The UAM survey also includes those PWID
who are not currently accessing addiction treatment services that
report data to NDTMS. It is also possible that the data reported
to NTDMS by treatment services will not fully capture the extent
of vaccine uptake among their clients, for example, if vaccination
has been delivered elsewhere or is not correctly recorded. Finally,
NDTMS data are for England only, whereas the data from the
UAM survey include Wales and Northern Ireland [19, 20].
Drug services are at the forefront of hepatitis B vaccine pro-
vision to PWID in the UK. There is evidence of a reduction in
funding for the provision of drug and alcohol services for both
adults and young people between 2013–14 and 2015–16 [14]. In
England, local government is responsible for commissioning
drug and alcohol services and receives a public health grant
from central government. The drug and alcohol services elem-
ent of this funding is not protected and drug and alcohol ser-
vices have had to compete with other public health priorities
for resources [14]. The commissioning of these services often
involves regular retendering and this can disrupt service deliv-
ery. In Wales, local health boards and three NHS trusts deliver
drug and alcohol services. Within the local health boards, local
authorities formulate and implement strategies for drugs and
alcohol. Northern Ireland has a fully integrated system for
both health and social care which oversee the provision of ser-
vices. As large number of organisations are involved in the com-
missioning of the services used by PWID, resourcing improved
Table 1. (Continued.)
Characteristica Total Number vaccinated (%) P Adjusted odds ratio, with 95%
confidence interval
Prescribed treatment for drug use
Never prescribed 500 299 59.8 <0.001 1.00
Previously prescribed 509 387 76.0 1.85 1.38 2.46
Currently prescribed 2129 1738 81.6 2.50 1.99 3.13
Used A&E
No 2120 1611 76.0 0.015 b
Yes 1018 813 79.9
Used walk-in clinic
No 2544 1945 76.5 0.028 b
Yes 594 479 80.6
aNo associations with gender, sharing injecting equipment in the last year, injected cocaine in the last year, injected speed during the preceding 12 months, injected other drugs in the
preceding 12 months, visiting a family planning clinic in the preceding 12 months.
bEntered in the multivariate analyses but not included in the final model.
Fig. 3. PWID in contact with service in the last year and not vaccinated for hepatitis B.
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delivery of hepatitis B vaccine for PWID may thus be
challenging.
One of the ways to increase the uptake of vaccination that has
been discussed is contingency management (CM). This involves
providing rewards when desired behaviour is achieved. CM can
be used alone or in combination with other treatment methods
and can be varied to suit the client’s needs. The two common
types of CM are voucher-based reinforcement and prize incen-
tives CM [23]. In addition to increasing uptake of vaccine [24],
this incentive-based approach has been found to be cost-effective
[25] as well as effective in encouraging the completion of hepatitis
B vaccine dose among heroin users undergoing addiction treat-
ment [26]. Although the use of this technique has been consid-
ered and guidelines for its implementation developed [27], CM
has so far not been widely implemented in the UK. The introduc-
tion of CM is potentially complex, for example, it requires the
training of staff in its delivery and robust monitoring systems
are needed for its effective implementation.
Our analysis also indicates that drug treatment services and
prisons were the main sources of hepatitis B vaccination. In an
earlier study in 2004, prison services were the most common
reported sources of vaccine doses, as a result the prison vaccin-
ation programme initiated in England in 2001 [17]. Our data indi-
cate that although the drug treatment services have overtaken
prisons, prisons and NSPs remain important sources of hepatitis
B vaccine provision. Prisons are important as they can reach some
of those at risk of injecting before initiation. NSP can reach those
recently initiated to injecting, and so have recently become at
higher risk [18]. NSPs are among the first services that PWID
come into contact with, with a vast majority of PWIDs in the
UK reporting the first use of an NSP shortly after starting to inject
[17]. It is thus of concern that in those who reported not been
vaccinated, NSPs were the most commonly used service, 80%
had used an NSP in the previous year.
Fewer participants reported receiving vaccination at GPs and
A&E services. This may be due to PWID not disclosing their
injecting drug use to health care professional when using these
services due to concerns about negative responses [1, 28, 29].
Structural barriers increase vulnerability and can also prevent
equitable access to services [1]. Our findings highlight an oppor-
tunity for primary and emergency care settings to engage more
with the PWID who attend these services and the need to increase
the offer of vaccination, and possibly the need for training to bet-
ter equip health care professionals in these services to do this
effectively.
Our data indicate that despite contact with services in the pre-
vious year that can offer HBV vaccination to high-risk groups, a
considerable proportion of vaccine-eligible PWID missed an
opportunity to be vaccinated during service contact. There there-
fore exists an opportunity to increase the level of vaccine delivery
in all services.
Factors associated with hepatitis B vaccine uptake
Younger participants (<30 years old) were less likely to be vacci-
nated and are therefore at a higher risk of acquiring hepatitis
B. Younger injectors are more likely to be recent initiates to inject-
ing and so less likely to have accessed specialist services for
PWID, such as drug services, and they may therefore not have
had the opportunity to be vaccinated. A higher proportion of
PWID are vulnerable to hepatitis B infection during the first
years of injection [12, 18]. This finding highlights the need for
approaches to increase uptake among young PWIDs and to recent
initiates to injecting. These could include offering vaccine at first
use of NSP, or targeting the populations where the risk of initi-
ation to injection may be elevated such as those in contact with
the criminal justice system.
Vaccine uptake was associated with the region of residence,
those in London being more likely to be vaccinated than those
living in any of the other regions outside of London. London
has a particularly high burden of hepatitis B; the incidence
rate of acute hepatitis B in London in 2012 was 2.02 per 100
000 population, which is twice the national rate (England rate
1.04 per 100 000) and much higher than that seen in any of
the other regions [30]. London has a higher prevalence (27%)
of PWID ever infected with hepatitis B compared with the rest
of England [19]. It is possible that the higher prevalence has
led to larger effort resulting in a larger proportion of this risk
group having been reached through targeted vaccination efforts
in London.
Vaccine uptake was higher in those currently in treatment for
their drug use than in those who have never been in treatment or
those previously but not currently in treatment. This probably
reflects the efforts to improve vaccine provision through these ser-
vices. BBV testing and vaccine uptake levels are being used in the
monitoring of the outcomes of drug treatment services in
England, and as a result there have been recent efforts to increase
BBV testing and vaccination [31]. Services have thus had BBV test-
ing and awareness campaigns, including, for example, increased
offer of testing around World Hepatitis Day. The promotion of
BBV testing may also increase vaccine uptake as those testing hepa-
titis B-negative will be encouraged to be vaccinated.
Those in contact with NSP in the past but not currently were
more likely to be vaccinated than those who had used the service
during the previous year. NSPs provide a mix of services [32] and
though they continue to be an important service for vaccine pro-
vision, NSPs role in providing this service might have reduced in
the recent past possibly due to the recent reductions in overall
funding for drug and alcohol services.
Those who had ever been to prison were more likely to have
been vaccinated. The UK prison hepatitis B vaccination pro-
gramme will probably have provided vaccine to many PWID
and will also have reached a substantial number of people at
risk of starting to inject [17]. However, our findings indicate a
potential to further improve vaccine uptake in prisons. Nearly a
half (49% (352)) of those who were unvaccinated reported having
ever been imprisoned in the past.
An opt-out testing policy for BBVs was introduced in English
prisons in 2013 [33]. As part of this policy, all prisoners found to
be at risk are offered the super-accelerated hepatitis B vaccination
(days 0, 7 and 21) with the first dose preferably provided on
reception into the prison. Although there are concerns related
to the funding of additional tests, time constraints and challenges
with taking of samples, staff resources and training needs, prelim-
inary data suggest a near doubling of BBV testing following the
introduction of the opt-out testing policy [34], which may in
turn lead to improved HBV vaccine uptake.
Participants reporting attending a GUM/STI clinic in the pre-
vious year were more likely to be vaccinated than those who had
not used these services. This possibly reflects the routine offer of
hepatitis B vaccine at these services, due to sexual contact cur-
rently being a more common transmission route for hepatitis B
in the UK [12]. Sexually active PWIDs, as well as those engaged
in transactional sex, were also more likely to be vaccinated,
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possibly reflecting higher levels of contact with sexual health ser-
vices among these groups.
Although being vaccinated for hepatitis B was associated with
attendance at a GP service in the previous year, there exists a
potential to increase uptake at GP services as a large proportion
(61% (437)) of those not vaccinated reported attending a GP ser-
vice the previous year. This may be because GPs may not be cor-
rectly identifying all PWID in their population, or that PWID
may not declare that they inject drugs. Additionally under the
GP services contract agreement, the provision of hepatitis B vac-
cine to those at risk due to lifestyle or medical risk is not part of
an additional list of services that GPs are required to provide [35].
Limitations
This analysis has a number of limitations. It assumes that those
who have not been vaccinated have not been offered the vaccine.
It is likely that some of those not vaccinated may have been offered
the vaccine but declined it. Recruiting a representative sample of
PWID is difficult as there is no sampling frame for this margina-
lised population. To maximise representativeness, this survey
used an accepted approach for surveillance surveys of PWID
involving recruitment at multiple sentinel locations through ser-
vices targeted at PWID [36, 37]. In the UK, there is a very extensive
provision of such targeted services, and the uptake and use of these
is very high, with very few of the PWID recruited through
community-based studies (i.e. recruiting outside services) found
not to be in contact with such services [38].
The behavioural data used here are based on self-reports.
People may be unaware that they have been vaccinated or may
not remember exactly what they may have been vaccinated for.
The presence of antibody to the HBsAg (anti-HBs) is indicative
of immunity to the HBV. Testing UAM samples for anti-HBs
in the future could confirm vaccination status as reported by par-
ticipants. The accuracy of behavioural data may be subject to
recall bias. However, the reliability of self-reported risk behaviours
among PWID has been shown in other studies [39, 40].
Conclusion
Unvaccinated PWID remain at risk of acquiring hepatitis
B. Improved and more efficient approaches to the delivery of hepa-
titis B vaccine to this group need to be developed and evaluated.
Additional resources will probably be needed to improve uptake,
but currently, obtaining these is likely to be challenging. In addition,
improving performance monitoring through the development of
better information systems that ensure efficient, accurate and timely
recording of data within and between services, as well as developing
staff skills, will be needed. As part of the overall goal to eliminate
viral hepatitis by 2030, eliminating hepatitis B among PWID
through vaccination coverage may be achievable, but is likely to
require changes in the delivery of services for this group.
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